The fallout from the U.S. crackdown on Huawei intensified this week, as trade negotiations between Washington and Beijing reportedly hit a roadblock.Asia Marketsread more
The issue of corporate debt has surfaced as companies continue to use the low rates the Fed has provided to lever up their balance sheets.The Fedread more
The U.S. government on Monday temporarily eased some trade restrictions imposed recently on China's Huawei, a move that sought to minimize disruption for the telecom company's...Technologyread more
Google has decided to stop licensing its Android operating system to Huawei, in order to comply with a U.S. trade blacklist.Technologyread more
Most U.S. hedge funds aren't expecting another big stock market sell-off as more firms curb bets on volatility, according to Nomura.Marketsread more
Mall owners are increasingly building out food halls with local chef-driven eateries, sushi bars and premium coffee shops.Retailread more
While Trump's lawyers had argued that the committee's subpoena did not have a legitimate legislative purpose — and was therefore invalid — Mehta took a broader view.Politicsread more
See which stocks are posting big moves after the bell on Monday, May 20.Market Insiderread more
Silicon Valley argues that Wall Street focuses too much on near-term profits — but investors have embraced money-losing biotech IPOs.Marketsread more
Iran has quadrupled its output of nuclear material amid rising tension with the U.S. and dangerous escalations in the Middle East.Energyread more
The announcement comes amid a wave of store closures across the country this year.Retailread more
One of the most exciting privately held companies in Silicon Valley came under fire on Thursday. Theranos has been viewed by some as a revolutionary company, and has been valued at as much at $9 billion in its most recent round of fundraising.
Theranos is a diagnostics company with fast finger-prick blood testing technology that aims to upend the traditional health care establishments by making it easier, less expensive and less uncomfortable to get tested for various conditions.
However the company also has critics, as The Wall Street Journal ran an article about Theranos alleging that the company's proprietary testing devices may be inaccurate. The Journal cited a former employee that claimed that of the 240 tests offered by Theranos, only 15 are actually performed on the company's proprietary Edison diagnostic machine, with the vast majority done on traditional lab equipment.
"That article was pretty brutal," the "Mad Money " host said. A WSJ representative earlier told CNBC the newspaper "fully stands by [author] John Carreyrou's article about Theranos, which was richly sourced and thoroughly researched."
With that in mind, Cramer always likes to make sure both sides of a story are represented. That is why he spoke with Elizabeth Holmes, the founder and CEO of Theranos, to give her a chance to provide her perspective.
The CEO speculated the reason why Theranos has garnered so much attention and scrutiny, stating "This is what happens when you work to change things, and first they think you're crazy, then they fight you and then all of a sudden you change the world," Holmes said. (Tweet this)
Holmes said she was personally shocked to see that The Journal would publish the article, as her company had purportedly sent the WSJ more than 1,000 pages of documentation that allegedly refuted the statements in the story.
Read more from Mad Money with Jim Cramer
"But we are doing things differently and we are working to make a difference and that means people raise questions, and that's okay," she said.
Holmes also added that Theranos offered to bring its technology to The Journal offices; she claimed they turned down that request.